Vanda Pharmaceuticals (VNDA) Q1 2025 earnings summary

Executive summary

• Entered a new growth phase with multiple commercialized products and a robust pipeline, including Fanapt, Hetlioz, and Ponvory, with additional NDAs and BLAs in progress; workforce surpassed 400 employees, a 22-year high.

• Fanapt's commercial growth accelerated, with weekly prescriptions surpassing 2,000, strong double-digit sales growth, and a significant expansion of the sales force.

• Recent regulatory filings for tradipitant, Bysanti, and Imsidolimab highlight ongoing R&D productivity and clinical milestones.

• Commercial launches of Fanapt for bipolar I disorder and Ponvory in relapsing multiple sclerosis contributed to increased sales and operating costs.

• Net loss widened to $29.5 million from $4.1 million in Q1 2024, reflecting a $15 million payment for Imsidolimab and increased commercial activity.

Financial highlights

• Q1 2025 total revenues were $50 million, up 5% year-over-year from $47.5 million.

• Fanapt net product sales rose 14% to $23.5 million; Hetlioz sales increased 4% to $20.9 million; Ponvory sales declined 18% to $5.6 million.

• Operating expenses increased to $91.1 million from $56.7 million, driven by R&D, SG&A, and legal costs.

• Cash and equivalents stood at $340.9 million at quarter-end, down $33.7 million sequentially.

• Diluted net loss per share was $0.50 in Q1 2025 versus $0.07 in Q1 2024.

Outlook and guidance

• 2025 revenue guidance reiterated at $210–$250 million, implying 6–26% growth over 2024; year-end 2025 cash expected between $280–$320 million.

• Revenue growth expected to be back-weighted as Fanapt and Ponvory ramp up; Hetlioz revenue may decline due to generic competition.

• Multiple regulatory milestones anticipated in 2025–2026, including FDA action dates for tradipitant and Bysanti and a BLA submission for Imsidolimab.